Statistiche di base
| LEI | 549300W3VKC5ZKMO8C28 |
| CIK | 1275187 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to AngioDynamics, Inc.
SEC Filings (Chronological Order)
Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.
| July 18, 2025 |
Exhibit 21 Subsidiaries of AngioDynamics, Inc. Subsidiary State of Incorporation or Organization AngioDynamics UK Limited United Kingdom AngioDynamics Netherlands B. V. Netherlands RITA Medical Systems, LLC Delaware AngioDynamics France, SARL France AngioDynamics Canada Inc. Canada AngioDynamics Medical Brasil Servicos de Marketing Ltda. Brazil Eximo Medical, Ltd. Israel AngioDynamics Italy S.r.l |
|
| July 18, 2025 |
Privileged and Confidential AngioDynamics, Inc. Executive Compensation Recoupment Policy (Effective October 2, 2023) This policy (“Policy”) sets forth the conditions under which AngioDynamics, Inc. (the “Company”) will seek reimbursement of certain compensation paid or payable to current or former executive officers of the Company who are subject to recoupment pursuant to this Policy (“Grantees”). |
|
| July 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended May 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-50761 AngioDynamics, Inc. (Exact name o |
|
| July 18, 2025 |
Title: Insider Trading Policy Function: Law Page: 1 of 10 Reviewed: 2/22 Effective: 3/1/22 Supersedes: GN 078, Rev 02 Insider Trading Policy Purpose As a public company, AngioDynamics Inc. |
|
| July 15, 2025 |
Exhibit 99.1 AngioDynamics Reports Strong Fiscal Year 2025 Fourth Quarter and Full Year Financial Results; Continued Execution Driving Accelerated, Profitable Growth Med Tech franchise delivers third consecutive quarter of over 20% revenue growth Reported strong adjusted EBITDA in the fourth quarter resulting in positive adjusted EBITDA for full fiscal year 2025 Drove $16.2 million of free cash fl |
|
| July 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2025 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| July 15, 2025 |
AngioDynamics Fourth Quarter and Full Year Earnings Presentation July 15, 2025 Exhibit 99.2 AngioDynamics Fourth Quarter and Full Year Earnings Presentation July 15, 2025 Forward-Looking Statements 2 Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash f |
|
| May 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2025 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| May 28, 2025 |
Exhibit 10.1 Execution Version CREDIT AGREEMENT dated as of May 28, 2025 among ANGIODYNAMICS, INC. as Borrower, The Lenders Party Hereto and JPMORGAN CHASE BANK, N.A., as Administrative Agent JPMORGAN CHASE BANK, N.A., as Sole Bookrunner and Sole Lead Arranger TABLE OF CONTENTS Page ARTICLE I Definitions 6 SECTION 1.01 Defined Terms 6 SECTION 1.02 Classification of Loans and Borrowings 43 SECTION |
|
| April 2, 2025 |
Exhibit 99.1 INVESTOR EVENT Shaping the Future of Cardiovascular Care: Innovative Technologies. Improved Outcomes. Forward Looking Statements Forward Looking Statements Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future f |
|
| April 2, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2025 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| April 2, 2025 |
Exhibit 99.2 AngioDynamics Third Quarter Fiscal Year 2025 Earnings Presentation April 2, 2025 Forward-Looking Statements 2 Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash |
|
| April 2, 2025 |
Quarter Ended February 28, 2025 Exhibit 99.1 AngioDynamics Reports Fiscal Year 2025 Third Quarter Financial Results LATHAM, N.Y.-(BUSINESS WIRE)— April 2, 2025- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial re |
|
| April 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Content UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 28, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-50761 Ang |
|
| April 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2025 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| January 16, 2025 |
Exhibit 99.1 J.P. Morgan 43rd Annual Healthcare Conference January 16, 2025 Jim Clemmer, President & CEO Forward looking statements 2 Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of opera |
|
| January 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2025 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| January 8, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2025 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| January 8, 2025 |
Exhibit 99.1 1 Edit Title 1 2 2 Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, compet |
|
| January 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2025 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| January 8, 2025 |
Quarter Ended November 30, 2024 Exhibit 99.1 AngioDynamics Reports Fiscal Year 2025 Second Quarter Financial Results LATHAM, N.Y.-(BUSINESS WIRE)— Jan 8, 2025- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial res |
|
| January 8, 2025 |
AngioDynamics Second Quarter Fiscal Year 2025 Earnings Presentation January 8, 2025 Exhibit 99.2 AngioDynamics Second Quarter Fiscal Year 2025 Earnings Presentation January 8, 2025 Forward-Looking Statements 2 Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, c |
|
| January 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Content UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-50761 Ang |
|
| November 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| October 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2024 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| October 3, 2024 |
Exhibit 99.1 AngioDynamics Reports Fiscal Year 2025 First Quarter Financial Results LATHAM, N.Y.-(BUSINESS WIRE)— Oct. 3, 2024- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial res |
|
| October 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Content UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended August 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-50761 Angio |
|
| October 3, 2024 |
Exhibit 99.2 AngioDynamics First Quarter Fiscal Year 2025 Earnings Presentation October 3, 2024 Forward-Looking Statements 2 Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, ca |
|
| September 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| September 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| July 25, 2024 |
Privileged and Confidential AngioDynamics, Inc. Executive Compensation Recoupment Policy (Effective October 2, 2023) This policy (“Policy”) sets forth the conditions under which AngioDynamics, Inc. (the “Company”) will seek reimbursement of certain compensation paid or payable to current or former executive officers of the Company who are subject to recoupment pursuant to this Policy (“Grantees”). |
|
| July 25, 2024 |
SETTLEMENT AND LICENSE AGREEMENT This SETTLEMENT AND LICENSE AGREEMENT (this “Agreement”) is made and entered into as of March 31, 2024 (the “Effective Date”), by and between (i) Becton, Dickinson and Company, a New Jersey corporation having a place of business at 1 Becton Drive, Franklin Lakes, New Jersey 07417, C. |
|
| July 25, 2024 |
Exhibit 21 Subsidiaries of AngioDynamics, Inc. Subsidiary State of Incorporation or Organization AngioDynamics UK Limited United Kingdom AngioDynamics Netherlands B. V. Netherlands RITA Medical Systems, LLC Delaware AngioDynamics France, SARL France AngioDynamics Canada Inc. Canada AngioDynamics Medical Brasil Servicos de Marketing Ltda. Brazil RadiaDyne LLC Texas Eximo Medical, Ltd. Israel AngioD |
|
| July 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended May 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-50761 AngioDynamics, Inc. (Exact name o |
|
| July 25, 2024 |
Title: Insider Trading Policy Function: Law Page: 1 of 10 Reviewed: 2/22 Effective: 3/1/22 Supersedes: GN 078, Rev 02 Insider Trading Policy Purpose As a public company, AngioDynamics Inc. |
|
| July 16, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2024 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| July 16, 2024 |
Exhibit 99.1 ANGIODYNAMICS, INC. AND SUBSIDIARIES PRO FORMA CONSOLIDATED INCOME STATEMENTS (in thousands, except per share data) Three Months Ended Three Months Ended As Reported (1) Pro Forma Adjustments (2) Pro Forma As Reported (1) Pro Forma Adjustments (2) Pro Forma Aug 31, 2023 Aug 31, 2023 Aug 31, 2023 Aug 31, 2022 Aug 31, 2022 Aug 31, 2022 (unaudited) (unaudited) Net sales $ 78,679 $ (11,93 |
|
| July 16, 2024 |
Exhibit 99.2 AngioDynamics Fourth Quarter and Full Year Earnings Presentation July 16, 2024 Forward-Looking Statements 2 Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash f |
|
| July 16, 2024 |
AngioDynamics Reports Fiscal Year 2024 Fourth Quarter and Full-Year Financial Results Exhibit 99.1 PRESS RELEASE Investor Contact: AngioDynamics, Inc. Stephen Trowbridge, Executive Vice President & CFO (518) 795-1408 AngioDynamics Reports Fiscal Year 2024 Fourth Quarter and Full-Year Financial Results LATHAM, N.Y.-(BUSINESS WIRE)-Jul. 16, 2024- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the |
|
| July 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2024 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| May 30, 2024 |
ANGO / AngioDynamics, Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ANGIODYNAMICS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities) 03475V101 (CUSIP Number) MAY 23, 2024 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which this |
|
| April 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Content UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 29, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-50761 Ang |
|
| April 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2024 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| April 4, 2024 |
Exhibit 99.2 AngioDynamics Third Quarter 2024 Earnings Presentation April 4, 2024 AngioDynamics First Quarter 2024 Earnings Forward-Looking Statement Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, |
|
| April 4, 2024 |
Exhibit 99.1 PRESS RELEASE Investor Contact: AngioDynamics, Inc. Stephen Trowbridge, Executive Vice President & CFO (518) 795-1408 AngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results; Updates Fiscal Year 2024 Guidance to Reflect Asset Divestiture Fiscal Year 2024 Third Quarter Highlights • Completed the sale of its PICC and Midline product portfolios to Spectrum Vascular on Febr |
|
| April 1, 2024 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2024 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| March 6, 2024 |
VIA EDGAR March 6, 2024 United States Securities and Exchange Commission Division of Corporate Finance Office of Industrial Applications and Services 100 F Street, N. |
|
| February 13, 2024 |
ANGO / AngioDynamics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0291-angiodynamicsinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)* Name of issuer: AngioDynamics Inc Title of Class of Securities: Common Stock CUSIP Number: 03475V101 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate |
|
| February 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2024 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| February 9, 2024 |
ANGO / AngioDynamics, Inc. / DIMENSIONAL FUND ADVISORS LP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 15 )* AngioDynamics Inc (Name of Issuer) Common Stock (Title of Class of Securities) 03475V101 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sch |
|
| January 23, 2024 |
ANGO / AngioDynamics, Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment SC 13G/A 1 ANGOSC13GA12024.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) ANGIODYNAMICS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities) 03475V101 (CUSIP Number) DECEMBER 31, 2023 (Date of event which requires filing of this statement) Check the appropr |
|
| January 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2024 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| January 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2024 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| January 11, 2024 |
Exhibit 99.1 J.P. Morgan Healthcare Conference January 11, 2024 Jim Clemmer, President & CEO A medical technology platform company focused on a select group of large, high growth markets where meaningful treatment gaps exist in current standard of care. We are transforming our portfolio to be a company focused on investing our resources on innovative technologies backed by science and clinical dat |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Content UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-50761 Ang |
|
| January 5, 2024 |
Exhibit 99.1 PRESS RELEASE Investor Contact: AngioDynamics, Inc. Stephen Trowbridge, Executive Vice President & CFO (518) 795-1408 AngioDynamics Reports Fiscal Year 2024 Second Quarter Financial Results; Revises Fiscal Year 2024 Guidance Fiscal Year 2024 Second Quarter Highlights • Net sales of $79.1 million increased 2.7% on a pro-forma basis compared to the prior-year quarter o Med Tech net sale |
|
| January 5, 2024 |
Exhibit 99.2 AngioDynamics Second Quarter 2024 Earnings Presentation January 5, 2024 AngioDynamics First Quarter 2024 Earnings Forward-Looking Statement Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial positio |
|
| January 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2023 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| October 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Content UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended August 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-50761 Angio |
|
| October 4, 2023 |
Exhibit 99.2 AngioDynamics First Quarter 2024 Earnings Presentation October 4, 2023 AngioDynamics First Quarter 2024 Earnings Forward-Looking Statement Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position |
|
| October 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2023 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| October 4, 2023 |
Exhibit 99.1 PRESS RELEASE Investor Contact: AngioDynamics, Inc. Stephen Trowbridge, Executive Vice President & CFO (518) 795-1408 AngioDynamics Reports Fiscal Year 2024 First Quarter Financial Results; Reaffirms Fiscal Year 2024 Guidance Fiscal Year 2024 First Quarter Highlights • Net sales of $78.7 million as reported o Includes $0.7 million of Dialysis and BioSentry Biopsy Tract Sealant System |
|
| September 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| September 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| September 12, 2023 |
ANGO / Angiodynamic Inc / MILLENNIUM MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ANGIODYNAMICS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities) 03475V101 (CUSIP Number) SEPTEMBER 5, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which |
|
| August 3, 2023 |
Exhibit 21 Subsidiaries of AngioDynamics, Inc. Subsidiary State of Incorporation or Organization AngioDynamics UK Limited United Kingdom AngioDynamics Netherlands B. V. Netherlands RITA Medical Systems, LLC Delaware AngioDynamics France, SARL France AngioDynamics Canada Inc. Canada AngioDynamics Medical Brasil Servicos de Marketing Ltda. Brazil RadiaDyne LLC Texas Eximo Medical, Ltd. Israel AngioD |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended May 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-50761 AngioDynamics, Inc. (Exact name o |
|
| July 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2023 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| July 24, 2023 |
AngioDynamics Announces Addition of Lorinda Burgess to Board of Directors Exhibit 99.1 NEWS RELEASE Investor Relations Contact: Media Contacts: Stephen Trowbridge Saleem Cheeks 518-795-1408 518-795-1174 [email protected] [email protected] AngioDynamics Announces Addition of Lorinda Burgess to Board of Directors LATHAM, NY, July 24, 2023 – AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring |
|
| July 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 12, 2023 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| July 12, 2023 |
Exhibit 99.1 PRESS RELEASE Investor Contact: AngioDynamics, Inc. Stephen Trowbridge, Executive Vice President & CFO (518) 795-1408 AngioDynamics Reports Fiscal Year 2023 Fourth Quarter and Full-Year Financial Results; Issues Fiscal Year 2024 Guidance Fiscal Year 2023 Fourth Quarter Highlights • Net sales of $91.1 million increased 4.7% compared to the prior-year quarter o Med Tech net sales of $26 |
|
| July 12, 2023 |
Exhibit 99.2 ANGIODYNAMICS Fourth Quarter 2023 Earnings Presentation July 12, 2023 1 2 Forward-Looking Statement Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, bu |
|
| July 5, 2023 |
ANGO / Angiodynamic Inc / VICTORY CAPITAL MANAGEMENT INC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ( Amendment No. 6)* Angiodynamics Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03475V101 (CUSIP Number) June 30, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedul |
|
| June 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2023 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| June 14, 2023 |
Exhibit 2.1 EXECUTION VERSION ASSET PURCHASE AGREEMENT BY AND BETWEEN MERIT MEDICAL SYSTEMS, INC. AND ANGIODYNAMICS, INC. Dated as of June 8, 2023 TABLE OF CONTENTS ARTICLE 1 THE TRANSACTIONS 1.1 Purchased Assets 1 1.2 Excluded Assets 2 1.3 Assumed Liabilities 3 1.4 Excluded Liabilities 4 1.5 Non-Assignable Assets 5 1.6 Shared Contracts 6 ARTICLE 2 CONSIDERATION FOR TRANSFER 2.1 Purchase Price and |
|
| June 14, 2023 |
Exhibit 99.1 AngioDynamics, Inc. Unaudited Pro Forma Condensed Consolidated Financial Statements AngioDynamics, Inc. and Subsidiaries UNAUDITED PRO FORMA CONSOLIDATED STATEMENTS OF OPERATIONS Nine Months Ended February 28, 2023 (in thousands of dollars, except per share data) As Reported (a) Pro Forma Adjustments Notes As Adjusted Net sales $ 247,678 $ (23,690 ) (b) $ 223,988 Cost of sales (exclus |
|
| June 8, 2023 |
Exhibit 99.1 PRESS RELEASE Investor Contact: AngioDynamics, Inc. Stephen Trowbridge, Executive Vice President & CFO (518) 795-1408 AngioDynamics Announces Sale of Dialysis Product Portfolio and BioSentry Product to Merit Medical Systems for $100 Million Announces preliminary Fiscal Year 2023 net sales in the range of $338 million to $339 million Latham, New York, June 8, 2023 – AngioDynamics, Inc. |
|
| June 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2023 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| June 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2023 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| April 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2023 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| April 17, 2023 |
Exhibit 99.1 Needham & Company 22nd Annual Virtual Healthcare Conference April 17, 2023 Jim Clemmer, President & CEO Stephen Trowbridge, Executive Vice President & CFO 2 Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 28, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-50761 An |
|
| March 30, 2023 |
AngioDynamics Reports Fiscal 2023 Third Quarter Financial Results; Revises Guidance Exhibit 99.1 PRESS RELEASE Investor Contact: AngioDynamics, Inc. Stephen Trowbridge, Executive Vice President & CFO (518) 795-1408 AngioDynamics Reports Fiscal 2023 Third Quarter Financial Results; Revises Guidance Fiscal Year 2023 Third Quarter Highlights • Net sales of $80.7 million increased 9.1% compared to the prior-year quarter o Med Tech net sales of $22.9 million increased 16.6% o Med Devi |
|
| March 30, 2023 |
Exhibit 99.2 ANGIODYNAMICS Third Quarter 2023 Earnings Presentation March 30, 2023 1 2 Forward-Looking Statement Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, bu |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2023 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| March 6, 2023 |
Exhibit 99.1 Raymond James 44th Annual Institutional Investors Conference March 6, 2023 Jim Clemmer, President & CEO Stephen Trowbridge, Executive Vice President & CFO 2 Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future |
|
| March 6, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2023 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| February 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2023 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| February 10, 2023 |
ANGO / AngioDynamics, Inc. / DIMENSIONAL FUND ADVISORS LP - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 14 )* AngioDynamics Inc (Name of Issuer) Common Stock (Title of Class of Securities) 03475V101 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| February 9, 2023 |
ANGO / AngioDynamics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: AngioDynamics Inc. Title of Class of Securities: Common Stock CUSIP Number: 03475V101 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ |
|
| February 6, 2023 |
ANGO / AngioDynamics, Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) ANGIODYNAMICS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities) 03475V101 (CUSIP Number) DECEMBER 31, 2022 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule |
|
| January 31, 2023 |
ANGO / AngioDynamics, Inc. / VICTORY CAPITAL MANAGEMENT INC Passive Investment SC 13G/A 1 angiodynamics13ga5123122.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ( Amendment No. 5)* Angiodynamics Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03475V101 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to desig |
|
| January 12, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2023 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| January 12, 2023 |
Exhibit 99.1 J.P. Morgan Healthcare Conference January 12, 2023 Jim Clemmer, President & CEO Stephen Trowbridge, Executive Vice President & CFO 2 Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, resu |
|
| January 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-50761 An |
|
| January 6, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) AngioDynamics, Inc. |
|
| January 6, 2023 |
As filed with the Securities and Exchange Commission on January 6, 2023 As filed with the Securities and Exchange Commission on January 6, 2023 Registration No. |
|
| January 5, 2023 |
Exhibit 99.2 ANGIODYNAMICS Second Quarter 2023 Earnings Presentation January 5, 2023 1 2 Forward-Looking Statement Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics? expected future financial position, results of operations, cash flows, |
|
| January 5, 2023 |
AngioDynamics Reports Fiscal 2023 Second Quarter Financial Results; Reaffirms Guidance Exhibit 99.1 PRESS RELEASE Investor Contact: AngioDynamics, Inc. Stephen Trowbridge, Executive Vice President & CFO (518) 795-1408 AngioDynamics Reports Fiscal 2023 Second Quarter Financial Results; Reaffirms Guidance Fiscal Year 2023 Second Quarter Highlights ? Net sales of $85.4 million increased 9.1% compared to the prior-year quarter ? Med Tech net sales of $24.5 million increased 29.7% ? Med |
|
| January 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2023 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| December 15, 2022 |
ANGO / AngioDynamics, Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ANGIODYNAMICS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities) 03475V101 (CUSIP Number) DECEMBER 12, 2022 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which |
|
| November 30, 2022 |
Exhibit 99.1 11 | 30 | 2022 ANGIODYNAMICS Piper Sandler Healthcare Conference Jim Clemmer, President & CEO Stephen Trowbridge, Executive VP & CFO 1 2 Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, |
|
| November 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2022 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 23, 2022 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2022 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| October 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| October 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended August 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-50761 Angi |
|
| October 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 6, 2022 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| October 6, 2022 |
AngioDynamics Reports Fiscal 2023 First Quarter Financial Results; Reaffirms Guidance Exhibit 99.1 PRESS RELEASE Investor Contact: AngioDynamics, Inc. Stephen Trowbridge, Executive Vice President & CFO (518) 795-1408 AngioDynamics Reports Fiscal 2023 First Quarter Financial Results; Reaffirms Guidance Fiscal Year 2023 First Quarter Highlights ? Net sales of $81.5 million increased 5.9% compared to the prior-year quarter o Med Tech net sales of $22.8 million increased 29.6% o Med De |
|
| October 6, 2022 |
Exhibit 99.2 ANGIODYNAMICS First Quarter 2023 Earnings Presentation October 6, 2022 1 2 Forward-Looking Statement Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics? expected future financial position, results of operations, cash flows, b |
|
| October 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 6, 2022 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| September 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| September 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| August 31, 2022 |
Exhibit 10.1 CREDIT AGREEMENT dated as of August 30, 2022 among ANGIODYNAMICS, INC. The Lenders Party Hereto JPMORGAN CHASE BANK, N.A. as Administrative Agent and BANK OF AMERICA, N.A. and KEYBANK NATIONAL ASSOCIATION as Syndication Agents JPMORGAN CHASE BANK, N.A., as Sole Bookrunner and Sole Lead Arranger TABLE OF CONTENTS Page ARTICLE I Definitions 1 SECTION 1.01. Defined Terms 1 SECTION 1.02. |
|
| August 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 30, 2022 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| August 10, 2022 |
Exhibit 99.1 08 | 10 | 2022 ANGIODYNAMICS Canaccord Growth Conference Stephen Trowbridge, EVP & CFO 1 2 Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics? expected future financial position, results of operations, cash flows, business st |
|
| August 10, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2022 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| July 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended May 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-50761 AngioDynamics, Inc. (Exact name o |
|
| July 22, 2022 |
Exhibit 21 Subsidiaries of AngioDynamics, Inc. Subsidiary State of Incorporation or Organization Vortex Medical, Inc. Delaware NM Holding Company, Inc. Delaware Navilyst Medical Holdings, Inc. Delaware Navilyst Medical, Inc. Delaware AngioDynamics UK Limited United Kingdom AngioDynamics Netherlands B. V. Netherlands RITA Medical Systems, LLC Delaware AngioDynamics France, SARL France AngioDynamics |
|
| July 12, 2022 |
Exhibit 99.1 PRESS RELEASE Investor Contact: AngioDynamics, Inc. Stephen Trowbridge, Executive Vice President & CFO (518) 795-1408 AngioDynamics Reports Fiscal Year 2022 Fourth Quarter and Full-Year Financial Results; Issues Fiscal Year 2023 Guidance Fiscal Year 2022 Fourth Quarter Highlights ? Net sales of $87.0 million increased 13.2% compared to the prior-year quarter ? Gross margin of 53.4% de |
|
| July 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 12, 2022 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| July 12, 2022 |
Exhibit 99.2 ANGIODYNAMICS Fourth Quarter 2022 Earnings Presentation July 12, 2022 1 2 Forward-Looking Statement Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics? expected future financial position, results of operations, cash flows, bu |
|
| April 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 28, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-50761 An |
|
| April 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 7, 2022 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| April 7, 2022 |
Exhibit 99.1 PRESS RELEASE Investor Contact: AngioDynamics, Inc. Stephen Trowbridge, Executive Vice President & CFO (518) 795-1408 AngioDynamics Reports Fiscal 2022 Third Quarter Financial Results; Reaffirms Fiscal Year 2022 Guidance Fiscal 2022 Third Quarter Highlights ? Net sales of $74.0 million increased 3.9% compared to the prior-year quarter ? Med Tech grew 28.6% and Med Device declined 2.8% |
|
| April 7, 2022 |
Exhibit 99.2 ANGIODYNAMICS Third Quarter 2022 Earnings PresentationApril 7, 2022 1 2 Forward-Looking Statement Notice Regarding Forward-Looking StatementsThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics? expected future financial position, results of operations, cash flows, busin |
|
| February 9, 2022 |
ANGO / AngioDynamics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: AngioDynamics Inc. Title of Class of Securities: Common Stock CUSIP Number: 03475V101 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ?? |
|
| February 8, 2022 |
ANGO / AngioDynamics, Inc. / DIMENSIONAL FUND ADVISORS LP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 13 )* AngioDynamics Inc (Name of Issuer) Common Stock (Title of Class of Securities) 03475V101 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sch |
|
| February 1, 2022 |
ANGO / AngioDynamics, Inc. / VICTORY CAPITAL MANAGEMENT INC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ( Amendment No. 4)* Angiodynamics Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03475V101 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sch |
|
| January 10, 2022 |
Exhibit 99.1 01 | 10 | 2022 ANGIODYNAMICS Needham Healthcare ConferenceJim Clemmer, President & CEO Stephen Trowbridge, EVP & CFO 1 2 Notice Regarding Forward-Looking StatementsThis presentation containsforward-looking statementswithin the meaning of the Private Securities Litigation Reform Act of 1995. All statementsregarding AngioDynamics? expected future financial position, resultsof operations |
|
| January 10, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| January 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-50761 An |
|
| January 6, 2022 |
Exhibit 99.2 ANGIODYNAMICS Second Quarter 2022 Earnings PresentationJanuary 6, 2022 1 2 Forward-Looking Statement Notice Regarding Forward-Looking StatementsThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics? expected future financial position, results of operations, cash flows, bu |
|
| January 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2022 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| January 6, 2022 |
Exhibit 99.1 PRESS RELEASE Investor Contact: AngioDynamics, Inc. Stephen Trowbridge, Executive Vice President & CFO (518) 795-1408 AngioDynamics Reports Fiscal 2022 Second Quarter Financial Results; Reaffirms Revenue Guidance; Revises Gross Margin and Adjusted EPS Guidance Fiscal 2022 Second Quarter Highlights ? Net sales of $78.3 million increased 7.6% compared to the prior-year quarter ? Med Tec |
|
| December 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2021 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| November 3, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2021 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| September 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2021 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| September 30, 2021 |
AngioDynamics Reports Fiscal 2022 First Quarter Financial Results; Updates Guidance Exhibit 99.1 PRESS RELEASE Investor Contact: AngioDynamics, Inc. Stephen Trowbridge, Executive Vice President & CFO (518) 795-1408 AngioDynamics Reports Fiscal 2022 First Quarter Financial Results; Updates Guidance Fiscal 2022 First Quarter Highlights ? Net sales of $77.0 million increased 9.6% compared to the prior-year quarter ? Gross margin of 52.1% increased 120 basis points year over year ? G |
|
| September 30, 2021 |
Exhibit 99.2 ANGIODYNAMICS First Quarter 2022 Earnings PresentationSeptember 30, 2021 * * Forward-Looking Statement Notice Regarding Forward-Looking StatementsThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics? expected future financial position, results of operations, cash flows, |
|
| September 30, 2021 |
Form of Performance Share Award Agreement pursuant to the 2020 Stock and Incentive Award Plan PERFORMANCE SHARE AWARD AGREEMENT This Performance Share Award Agreement (this ?Agreement?), dated as of the [ ] day of [ ], 20[ ] (the ?Grant Date?), is between AngioDynamics, Inc. |
|
| September 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended August 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-50761 Angi |
|
| September 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| September 22, 2021 |
DEF 14A 1 angoproxy-53121.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| August 5, 2021 |
ANGO / AngioDynamics, Inc. / VICTORY CAPITAL MANAGEMENT INC Passive Investment SC 13G/A 1 angiodynamics13ga373121.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ( Amendment No. 3)* Angiodynamics Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03475V101 (CUSIP Number) July 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate |
|
| July 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended May 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-50761 AngioDynamics, Inc. (Exact name o |
|
| July 27, 2021 |
Exhibit 21 Subsidiaries of AngioDynamics, Inc. Subsidiary State of Incorporation or Organization Vortex Medical Delaware NM Holding Company, Inc. Delaware Navilyst Medical Holdings, Inc. Delaware Navilyst Medical, Inc. Delaware AngioDynamics UK Limited United Kingdom AngioDynamics Netherlands B. V. Netherlands RITA Medical Systems, LLC Delaware AngioDynamics France, SARL France AngioDynamics Canad |
|
| July 13, 2021 |
Exhibit 99.2 ANGIODYNAMICS Fourth Quarter 2021 Earnings PresentationJuly 13, 2021 1 2 Forward-Looking Statement Notice Regarding Forward-Looking StatementsThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics? expected future financial position, results of operations, cash flows, busi |
|
| July 13, 2021 |
AngioDynamics Reports Fiscal 2021 Fourth Quarter and Full-Year Financial Results Exhibit 99.1 PRESS RELEASE Investor Contact: AngioDynamics, Inc. Stephen Trowbridge, Executive Vice President & CFO (518) 795-1408 AngioDynamics Reports Fiscal 2021 Fourth Quarter and Full-Year Financial Results Fiscal 2021 Fourth Quarter Highlights ? Net sales of $76.8 million increased 31.7% compared to the prior-year quarter ? Gross margin of 55.1% increased 330 basis points year over year ? GA |
|
| July 13, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2021 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| July 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2021 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| July 13, 2021 |
Exhibit 99.1 1 Investor & technology day JULY 2021 AGENDA 9:30 ? 10:50 AM ET | BUSINESS PRESENTATIONS ANGIODYNAMICS OVERVIEW GROWTH STRATEGY & TECHNOLOGY OVERVIEW KEY TECHNOLOGY PLATFORM OVERVIEW Thrombus management ? ANGIOVAC & ALPHAVAC PERIPHERAL ATHERECTOMY ? AURYON IRREVERSIBLE ELECTROPORATION ? NANOKNIFE VASCULAR ACCESS AND MED DEVICES GLOBAL HEALTHCARE ECONOMICS10:50 ? 11:00 AM ET | FINANCIA |
|
| May 25, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2021 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| May 25, 2021 |
Exhibit 99.1 05 | 25 | 2021 ANGIODYNAMICS The UBS 2021 Virtual Global Healthcare Conference Jim Clemmer, President & CEO 2 Forward-Looking Statement Notice Regarding Forward-Looking StatementsThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics? expected future financial position, re |
|
| April 12, 2021 |
Exhibit 99.1 04 | 12 - 15 | 2021 ANGIODYNAMICS The 20th Annual Needham Virtual Healthcare ConferenceJim Clemmer, President & CEOStephen Trowbridge, EVP & CFO 2 Forward-Looking Statement Notice Regarding Forward-Looking StatementsThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics? e |
|
| April 12, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2021 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| March 31, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 28, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-50761 An |
|
| March 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2021 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| March 30, 2021 |
AngioDynamics Reports Fiscal 2021 Third Quarter Financial Results and Updates Guidance Exhibit 99.1 PRESS RELEASE Investor Contact: AngioDynamics, Inc. Stephen Trowbridge, Executive Vice President & CFO (518) 795-1408 AngioDynamics Reports Fiscal 2021 Third Quarter Financial Results and Updates Guidance Fiscal 2021 Third Quarter Highlights ? Net sales of $71.2 million increased 2.0% compared to the prior-year quarter ? Gross margin of 54.1%, a decline of 370 basis points year over y |
|
| March 30, 2021 |
Exhibit 99.2 ANGIODYNAMICS Third Quarter 2021 Earnings PresentationMarch 30, 2021 1 2 Forward-Looking Statement Notice Regarding Forward-Looking StatementsThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics? expected future financial position, results of operations, cash flows, busi |
|
| March 9, 2021 |
Exhibit 99.1 03 | 09 | 2021 ANGIODYNAMICS Barclays Global Healthcare ConferenceJim Clemmer, President & CEOStephen Trowbridge, EVP & CFO 2 Forward-Looking Statement Notice Regarding Forward-Looking StatementsThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics? expected future financ |
|
| March 9, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2021 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 12 )* AngioDynamics Inc (Name of Issuer) Common Stock (Title of Class of Securities) 03475V101 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sch |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: AngioDynamics Inc. Title of Class of Securities: Common Stock CUSIP Number: 03475V101 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ |
|
| February 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2021 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| February 3, 2021 |
Form of Amended and Restated Change in Control Agreement with AngioDynamics, Inc. Exhibit 10.2 AMENDED AND RESTATED CHANGE IN CONTROL AGREEMENT THIS AMENDED AND RESTATED CHANGE IN CONTROL AGREEMENT (the “Agreement”), is made effective as of January 29, 2021 between AngioDynamics, Inc., a Delaware corporation (the “Company”), and [•], an individual resident of [•] (“Executive”). WHEREAS, the Company considers it essential to the best interests of its shareholders to foster the c |
|
| February 3, 2021 |
Exhibit 10.1 AMENDED AND RESTATED CHANGE IN CONTROL AGREEMENT THIS AMENDED AND RESTATED CHANGE IN CONTROL AGREEMENT (the “Agreement”), is made effective as of January 29, 2021 between AngioDynamics, Inc., a Delaware corporation (the “Company”), and James C. Clemmer, an individual resident of New York (“Executive”). WHEREAS, the Company considers it essential to the best interests of its shareholde |
|
| February 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ( Amendment No. )* Angiodynamics Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03475V101 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche |
|
| January 19, 2021 |
As filed with the Securities and Exchange Commission on October January 19, 2021 Registration No. |
|
| January 11, 2021 |
EX-99.1 2 an55606677-ex991.htm PRESENTATION SLIDES FOR THE 23RD ANNUAL NEEDHAM VIRTUAL GROWTH CONFERENCE, DATED JANUARY 11, 2021 Exhibit 99.1 01 | 11 | 2021 ANGIODYNAMICS 23rd Annual Needham Virtual Growth Conference Jim Clemmer, President & CEO 2 Forward-Looking Statement Notice Regarding Forward-Looking StatementsThis presentation contains forward-looking statements within the meaning of the Pri |
|
| January 11, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2021 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| January 8, 2021 |
PERFORMANCE SHARE AWARD AGREEMENT This Performance Share Award Agreement (this “Agreement”), dated as of the [ ] day of [ ], 2020 (the “Grant Date”), is between AngioDynamics, Inc. |
|
| January 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-50761 An |
|
| January 7, 2021 |
Exhibit 99.2 ANGIODYNAMICS Second Quarter 2021 Earnings PresentationJanuary 7, 2021 1 2 Forward-Looking Statement Notice Regarding Forward-Looking StatementsThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, bu |
|
| January 7, 2021 |
Exhibit 99.2 ANGIODYNAMICS Second Quarter 2021 Earnings PresentationJanuary 7, 2021 1 2 Forward-Looking Statement Notice Regarding Forward-Looking StatementsThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, bu |
|
| January 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2021 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| January 7, 2021 |
AngioDynamics Reports Fiscal 2021 Second Quarter Financial Results Exhibit 99.1 PRESS RELEASE Investor Contact: AngioDynamics, Inc. Stephen Trowbridge, Executive Vice President & CFO (518) 795-1408 AngioDynamics Reports Fiscal 2021 Second Quarter Financial Results Fiscal 2021 Second Quarter Highlights • Net sales of $72.8 million increased 4.0% compared to the prior-year quarter • Gross margin declined 410 basis points year over year to 55.2% • GAAP loss per shar |
|
| January 7, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2021 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) |
|
| November 19, 2020 |
Exhibit 99.1 11 | 19 | 2020 ANGIODYNAMICS Canaccord Genuity2020 Medical Technologies & Diagnostics Forum 2 Forward-Looking Statement Notice Regarding Forward-Looking StatementsThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operati |
|
| November 19, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2020 AngioDynamics, Inc (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| October 15, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2020 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| October 7, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended August 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-50761 Angi |
|
| September 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2020 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| September 29, 2020 |
AngioDynamics Reports Fiscal 2021 First Quarter Financial Results Exhibit 99.1 PRESS RELEASE Investor Contact: AngioDynamics, Inc. Stephen Trowbridge, Executive Vice President & CFO (518) 795-1408 AngioDynamics Reports Fiscal 2021 First Quarter Financial Results Fiscal 2021 First Quarter Highlights • Net sales of $70.2 million increased 6.3% compared to the prior-year quarter, inclusive of the previously disclosed $5.2 million order from the National Health Serv |
|
| September 29, 2020 |
Exhibit 99.2 AngioDynamics First Quarter 2021 Earnings PresentationSeptember 29, 2020 Notice Regarding Forward-Looking StatementsThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, pr |
|
| September 3, 2020 |
AngioDynamics, Inc. Employee Stock Purchase Plan (as amended). UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| September 3, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| August 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2020 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| August 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended May 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-50761 AngioDynamics, Inc. (Exact name o |
|
| August 10, 2020 |
Form of Severance Agreement of AngioDynamics, Inc. SEPARATION AGREEMENT AND GENERAL RELEASE This is a Separation Agreement and General Release (“Agreement”) between AngioDynamics, Inc. |
|
| August 10, 2020 |
Exhibit 21 Subsidiaries of AngioDynamics, Inc. Subsidiary State of Incorporation or Organization Vortex Medical Delaware NM Holding Company, Inc. Delaware Navilyst Medical Holdings, Inc. Delaware Navilyst Medical, Inc. Delaware AngioDynamics UK Limited United Kingdom AngioDynamics Netherlands B. V. Netherlands RITA Medical Systems, LLC Delaware AngioDynamics France, SARL France AngioDynamics Canad |
|
| July 16, 2020 |
Exhibit 99.2 AngioDynamics Fourth Quarter 2020 Earnings PresentationJuly 16, 2020 Notice Regarding Forward-Looking StatementsThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, projec |
|
| July 16, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 16, 2020 ANGIODYNAMICS INC (Exact Name of Registrant as Specified in Its Charter) 000-50761 (Commission File Number) Delaware 11-3146460 (State or Other Jurisdiction of Incorpora |
|
| July 16, 2020 |
AngioDynamics Reports Fiscal 2020 Fourth Quarter and Full-Year Financial Results Exhibit 99.1 PRESS RELEASE Investor Contact: AngioDynamics, Inc. Stephen Trowbridge, Executive Vice President & CFO (518) 795-1408 AngioDynamics Reports Fiscal 2020 Fourth Quarter and Full-Year Financial Results Fiscal 2020 Fourth Quarter Highlights • Net sales of $58.3 million decreased 18.1% compared to the prior-year quarter • Gross margin declined 630 basis points year over year to 51.8% • GAA |
|
| April 8, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 29, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-50761 An |
|
| April 8, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 7, 2020 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) ( |
|
| April 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 7, 2020 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| April 7, 2020 |
AngioDynamics Reports Fiscal 2020 Third Quarter Financial Results Exhibit 99.1 PRESS RELEASE Investor Contact: AngioDynamics, Inc. Stephen Trowbridge, Executive Vice President & CFO (518) 795-1408 AngioDynamics Reports Fiscal 2020 Third Quarter Financial Results Fiscal 2020 Third Quarter Highlights • Net sales of $69.8 million increased 6.5% compared to the prior-year quarter • Gross margin declined 40 basis points to 57.8% year over year • GAAP loss per share o |
|
| April 7, 2020 |
Exhibit 99.2 AngioDynamics Third Quarter 2020 Earnings PresentationApril 7, 2020 Notice Regarding Forward-Looking StatementsThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, project |
|
| February 12, 2020 |
ANGO / AngioDynamics, Inc. / DIMENSIONAL FUND ADVISORS LP - SCHEDULE 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 11)* ANGIODYNAMICS INC (Name of Issuer) Common Stock (Title of Class of Securities) 03475V101 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche |
|
| February 12, 2020 |
ANGO / AngioDynamics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: AngioDynamics Inc Title of Class of Securities: Common Stock CUSIP Number: 03475V101 Date of Event Which Requires Filing of this Statement: December 31, 2019 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ R |
|
| February 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 5, 2020 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| February 7, 2020 |
AngioDynamics Appoints Stephen Trowbridge Executive Vice President and Chief Financial Officer Exhibit 99.1 NEWS RELEASE Investor Relations Contact: Media Contact: AngioDynamics, Inc. Stephen Trowbridge 518-795-1408 [email protected] AngioDynamics, Inc. Saleem Cheeks 518-795-1174 [email protected] AngioDynamics Appoints Stephen Trowbridge Executive Vice President and Chief Financial Officer Latham, New York, February 6, 2020 – AngioDynamics, Inc. (NASDAQ: ANGO), a leadin |
|
| January 29, 2020 |
ANGO / AngioDynamics, Inc. / VICTORY CAPITAL MANAGEMENT INC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ( Amendment No. )* Angiodynamics Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03475V101 (CUSIP Number) December 31, 2019 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche |
|
| January 16, 2020 |
Exhibit 99.1 J.P. MORGAN HEALTHCARE CONFERENCEAngioDynamicsJim Clemmer, President and CEOJanuary 16, 2020 Notice Regarding Forward-Looking StatementsThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business s |
|
| January 16, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2020 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| January 8, 2020 |
Exhibit 21 Subsidiaries of AngioDynamics, Inc. Subsidiary State of Incorporation or Organization Vortex Medical Delaware NM Holding Company, Inc. Delaware Navilyst Medical Holdings, Inc. Delaware Navilyst Medical, Inc. Delaware AngioDynamics UK Limited United Kingdom AngioDynamics Netherlands B. V. Netherlands RITA Medical Systems, LLC Delaware AngioDynamics France, SARL France AngioDynamics Canad |
|
| January 8, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-50761 An |
|
| January 8, 2020 |
AngioDynamics 2019 Total Shareholder Return Performance Unit Agreement Program. PERFORMANCE SHARE AWARD AGREEMENT This Performance Share Award Agreement (this “Agreement”), dated as of the day of (the “Grant Date”), is between AngioDynamics, Inc. |
|
| January 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2020 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| January 7, 2020 |
Exhibit 99.2 AngioDynamics Second Quarter 2020 Earnings PresentationJanuary 7, 2020 Notice Regarding Forward-Looking StatementsThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, proj |
|
| January 7, 2020 |
AngioDynamics Reports Fiscal 2020 Second Quarter Financial Results EX-99.1 2 an54566078-991.htm PRESS RELEASE, DATED JANUARY 7, 2020 Exhibit 99.1 PRESS RELEASE Investor Contact: AngioDynamics, Inc. Stephen Trowbridge, SVP General Counsel and Interim CFO (518) 795-1408 AngioDynamics Reports Fiscal 2020 Second Quarter Financial Results Fiscal 2020 Second Quarter Highlights • Net sales of $70.0 million, flat compared to the prior-year quarter • Gross margin increase |
|
| November 20, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2019 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| October 22, 2019 |
AngioDynamics Announces Departure of CFO and Appointment of Interim CFO Exhibit 99.1 NEWS RELEASE Investor Relations Contact: Media Contact: AngioDynamics, Inc. Stephen Trowbridge 518-795-1408 [email protected] AngioDynamics, Inc. Saleem Cheeks 518-795-1174 [email protected] AngioDynamics Announces Departure of CFO and Appointment of Interim CFO Latham, New York, October 22, 2019 – AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovativ |
|
| October 22, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2019 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| October 18, 2019 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 15, 2019 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| October 4, 2019 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended August 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-50761 Angi |
|
| October 4, 2019 |
Exhibit 21 Subsidiaries of AngioDynamics, Inc. Subsidiary State of Incorporation or Organization Vortex Medical Delaware NM Holding Company, Inc. Delaware Navilyst Medical Holdings, Inc. Delaware Navilyst Medical, Inc. Delaware AngioDynamics UK Limited United Kingdom AngioDynamics Netherlands B. V. Netherlands RITA Medical Systems, LLC Delaware AngioDynamics France, SARL France AngioDynamics Canad |
|
| October 3, 2019 |
AngioDynamics Reports Fiscal 2020 First Quarter Financial Results Exhibit 99.1 PRESS RELEASE Investor Contact: AngioDynamics, Inc. Michael C. Greiner, Executive Vice President & CFO (518) 795-1821 AngioDynamics Reports Fiscal 2020 First Quarter Financial Results Fiscal 2020 First Quarter Highlights • Net sales of $66.0 million, an increase of 3.3% year over year • Gross margin increased 170 basis points year over year to 57.9% • GAAP loss per share of $0.03; adj |
|
| October 3, 2019 |
Exhibit 99.2 AngioDynamics First Quarter 2020 Earnings PresentationOctober 3, 2019 Notice Regarding Forward-Looking StatementsThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, proje |
|
| October 3, 2019 |
8-K 1 an54174464-8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2019 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdictio |
|
| October 3, 2019 |
AngioDynamics Acquires Eximo Medical, Ltd. and its Innovative 355nm Laser Atherectomy Technology Exhibit 99.3 NEWS RELEASE Investor Relations Contact: Media Contact: AngioDynamics, Inc. AngioDynamics, Inc. Michael Greiner Saleem Cheeks 518-795-1821 518-795-1174 [email protected] [email protected] AngioDynamics Acquires Eximo Medical, Ltd. and its Innovative 355nm Laser Atherectomy Technology Latham, New York, October 3, 2019 – AngioDynamics, Inc. (NASDAQ: ANGO), a leading pro |
|
| September 5, 2019 |
ANGO / AngioDynamics, Inc. DEFA14A - - DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| September 5, 2019 |
ANGO / AngioDynamics, Inc. DEF 14A - - DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| August 16, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2019 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| July 25, 2019 |
Exhibit 21 Subsidiaries of AngioDynamics, Inc. Subsidiary State of Incorporation or Organization Vortex Medical Delaware NM Holding Company, Inc. Delaware Navilyst Medical Holdings, Inc. Delaware Navilyst Medical, Inc. Delaware AngioDynamics UK Limited United Kingdom AngioDynamics Netherlands B. V. Netherlands RITA Medical Systems, LLC Delaware AngioDynamics France, SARL France AngioDynamics Canad |
|
| July 25, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended May 31, 2019 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-50761 AngioDynamics, Inc. (Exact name o |
|
| July 19, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2019 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| July 10, 2019 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2019 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| July 10, 2019 |
Exhibit 99.1 AngioDynamics Fourth Quarter 2019 Earnings PresentationJuly 10, 2019 Notice Regarding Forward-Looking StatementsThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, projec |
|
| July 10, 2019 |
AngioDynamics Reports Fiscal 2019 Fourth Quarter and Full-Year Financial Results Exhibit 99.1 PRESS RELEASE Investor Contact: AngioDynamics, Inc. Michael C. Greiner, Executive Vice President & CFO (518) 795-1821 AngioDynamics Reports Fiscal 2019 Fourth Quarter and Full-Year Financial Results Fiscal 2019 Fourth Quarter Highlights • Net sales of $96.3 million, an increase of 9.0% year over year and 5.2% organically • Gross margin of 53.6%, flat year-over-year • GAAP EPS of $1.54 |
|
| July 10, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2019 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| June 6, 2019 |
Exhibit 10.1 CREDIT AGREEMENT dated as of June 3, 2019 among ANGIODYNAMICS, INC. The Lenders Party Hereto JPMORGAN CHASE BANK, N.A. as Administrative Agent and BANK OF AMERICA, N.A. and KEYBANK NATIONAL ASSOCIATION as Syndication Agents JPMORGAN CHASE BANK, N.A., as Sole Bookrunner and Sole Lead Arranger TABLE OF CONTENTS Page ARTICLE I Definitions 1 SECTION 1.01. Defined Terms 1 SECTION 1.02. Cla |
|
| June 6, 2019 |
Exhibit 99.1 AngioDynamics, Inc. and Subsidiaries UNAUDITED PRO FORMA CONSOLIDATED STATEMENTS OF INCOME Nine Months Ended February 28, 2019 (in thousands of dollars, except per share data) As Reported (a) Pro Forma Adjustments Notes As Adjusted Net sales $ 263,184 $ (63,695 ) (b) $ 199,489 Cost of sales (exclusive of intangible amortization) 122,917 (38,115 ) (b) 84,802 Gross profit 140,267 (25,58 |
|
| June 6, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2019 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| June 6, 2019 |
AngioDynamics Completes Sale of NAMIC® Fluid Management Portfolio to Medline Industries, Inc. Exhibit 99.2 NEWS RELEASE Investor Relations Contact: Media Contact: AngioDynamics, Inc. Michael Greiner 518-795-1821 [email protected] AngioDynamics, Inc. Saleem Cheeks 518-795-1174 [email protected] AngioDynamics Completes Sale of NAMIC® Fluid Management Portfolio to Medline Industries, Inc. Latham, New York, June 3, 2019 – AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider |
|
| June 6, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2019 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| June 6, 2019 |
ANGO / AngioDynamics, Inc. / VICTORY CAPITAL MANAGEMENT INC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ( Amendment No. )* Angiodynamics Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03475V101 (CUSIP Number) May 31, 2019 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| April 18, 2019 |
Exhibit 99.1 AngioDynamics Divestiture Announcement: NAMIC Fluid Management BusinessApril 17, 2019 Forward-Looking Statements Notice Regarding Forward-Looking StatementsThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, ca |
|
| April 18, 2019 |
Exhibit 2.1 ASSET PURCHASE AGREEMENT dated as of April 17, 2019 by and between ANGIODYNAMICS, INC. and MEDLINE INDUSTRIES, INC. TABLE OF CONTENTS Page ARTICLE I DEFINITIONS Section 1.1 Definitions 1 Section 1.2 Construction 16 Section 1.3 Performance of Obligations by Affiliates 16 ARTICLE II PURCHASE AND SALE Section 2.1 Agreement to Purchase and Sell 17 Section 2.2 Excluded Assets 19 Section 2.3 |
|
| April 18, 2019 |
Exhibit 99.2 NEWS RELEASE Investor Relations Contact: Media Contacts: AngioDynamics, Inc. Michael Greiner 518-795-1821 [email protected] AngioDynamics, Inc. Saleem Cheeks 518-795-1174 [email protected] Medline Blair Klein 847-643-3308 [email protected] AngioDynamics Announces Agreement to Sell NAMIC® Fluid Management Business to Medline Industries, Inc. for $167.5 Million ● Angio |
|
| April 18, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2019 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| April 2, 2019 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2019 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| April 2, 2019 |
Exhibit 99.1 AngioDynamics Third Quarter 2019 Earnings PresentationApril 2, 2019 Forward-Looking Statements Notice Regarding Forward-Looking StatementsThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business |
|
| April 2, 2019 |
AngioDynamics Reports Fiscal 2019 Third Quarter Financial Results Exhibit 99.1 PRESS RELEASE Investor Contact: AngioDynamics, Inc. Michael C. Greiner, Executive Vice President & CFO (518) 795-1821 AngioDynamics Reports Fiscal 2019 Third Quarter Financial Results Fiscal 2019 Third Quarter Highlights ● Net sales of $86.3 million, an increase of 3.0% year over year ● Gross margin declined 10 basis points year over year to 54.1% ● GAAP EPS of $0.02 per share; adjust |
|
| April 2, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2019 AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-50761 11-3146460 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| April 2, 2019 |
ANGO / AngioDynamics, Inc. 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 28, 2019 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-50761 An |
|
| February 22, 2019 |
ANGO / AngioDynamics, Inc. REGISTRATION STATEMENT As filed with the Securities and Exchange Commission on February 22, 2019 Registration No. |
